THEASTON boosters, or TRH-20, are among the new treatments being tested in humans for a rare condition that causes men to have higher testosterone levels than normal, according to a team of scientists.
The condition is not uncommon, but few have reported symptoms, according the researchers.
A new study led by University of California, Los Angeles, professor of endocrinology, Andrew M. Siegel, reported on the findings Wednesday in the journal Nature.
One of the new therapies, called TRH20X, is made from a synthetic form of testosterone that has a lower level of testosterone than the human body.
TRH is an essential part of the body’s natural hormone production, and its production is regulated by several genes.
It has a high affinity for the testosterone receptor, or TERT.
TERTs are essential for cell growth, differentiation, and other processes.
Scientists have long known that testosterone can help women gain weight.
But testosterone has never been tested in women, and the study looked at a single woman.
The researchers were able to use a computerized technique to see how much testosterone was present in her body before and after the treatment.
They also found that the treatment affected the levels of the enzyme that produces and breaks down testosterone.
“These findings suggest that TRH may be useful as a therapy for hyperandrogenism, in which men have a higher level of circulating testosterone than normal,” the researchers wrote in the paper.
For the study, the researchers examined blood samples from women who had been given TRH and were followed for two years.
The team also analyzed samples of blood taken before and two years after the men had received the treatment for TRH.
While TRH was administered in a single dose, the treatment also increased the levels in the blood of a second group of women.
This second group had lower levels of TERT and more testosterone.
The second group also had higher levels of a protein called T4, which is a marker for inflammation.
When inflammation is high, it can trigger an autoimmune response.
Antibodies that recognize the T4 protein in the men’s blood were also elevated in the TRH group, suggesting that the men were experiencing an immune response to the TRT compound.
The investigators concluded that the new treatment did not cause any more symptoms than the previous treatment.
But the researchers say that the study is the first to demonstrate that TRPV1 and TERT are the same.
Some women with hyperandrology have been taking testosterone boosters for decades, and some have not.
In most cases, the hormone is taken for other health reasons, such as weight loss, and not for the condition.
The results of the study may help doctors decide whether the treatment is a good choice for men with hyperAndrogenism.
“We don’t know if TRH should be considered as a therapeutic option for men who are not taking TRP and have a healthy immune system,” said co-author Dr. Roberta S. G. Charette, a professor of medicine at the University of Washington.
“There is no consensus as to what TRH really is, but it may be beneficial for some patients.”
Follow LiveScience for the latest in science news and discoveries on Twitter @livescience and on Facebook.